5 days ago
Zydus acquires US biologics manufacturing facilities, Manufacturing News, ET Manufacturing
Advt
Homegrown pharma major Zydus Lifesciences on Tuesday announced it has entered the global biologics contract development and manufacturing ( CDMO ) space with the acquisition of two manufacturing facilities from US-based Agenus Inc. The company will pay $75 million upfront and up to $50 million in milestone-linked payments over three deal gives Zydus control of biologics manufacturing units in Emeryville and Berkeley California , providing immediate access to advanced development and production capabilities. The facilities will be housed under an independent CDMO entity within the group and serve global biotech and pharma firms. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local will also become the exclusive contract manufacturer for Agenus' two Phase 3-ready immuno-oncology candidates-Botensilimab and Balstilimab-for clinical and commercial supply. It has also secured the first right of negotiation to manufacture future Agenus pipeline Sharvil Patel, managing director, Zydus Lifesciences, said, "The acquisition gives Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry."The deal positions Zydus to benefit from growing global demand for biologics manufacturing, as governments and companies shift supply chains closer to key markets.
